CLOCK and glioblastoma: To investigate whether pharmacological modulation of the circadian clock affects GBM viability, T98G cells were treated with a CK1ε/δ inhibitor (PF670462), a GSK-3 inhibitor (CHIR99021), or a CRY protein stabilizer (KL001) in a range of concentrations from 0.01 to 100 μM for 48 h.